TITLE:
Serum CK18 as a Predictive Factor of Response to Chemotherapy in Locally Advanced and Metastatic Breast Cancer
AUTHORS:
Basem Battah, Jumana Saleh, Marroan Bachour, Maher Salamoon
KEYWORDS:
CK18, Metastatic Breast Cancer, Response
JOURNAL NAME:
Advances in Breast Cancer Research,
Vol.3 No.3,
June
30,
2014
ABSTRACT: Introduction: Breast
cancer is the most common cancer in women and the second most frequent cause of
cancer death. Several factors affect response to chemotherapy including nodal
status, hormonal status and human epidermal growth factor receptor (Her-2). Aim
of Study: The study is aiming at evaluating M30 antigen in serum of patients
with locally advanced and metastatic breast cancer and establishing the
relation between M30 level and response to chemotherapy. Patients and Methods:
The study was performed at Al Bairouni University Hospital and the Faculty of
Pharmacy (Damascus-Syria). We have included 60 patients with histologic
confirmation of invasive ductal carcinoma of the breast treated with the
combination (Docetaxel + Doxorubicin) with M30 levels to be evaluated before
treatment and 24 hours after the first and third cycle. Results: M30 level
increase in serum 24 hours after the 1st cycle correlated with different kinds
of response in 39 patients (P value
less than 0.03) with better results in those with Estrogen Receptors (ER)
positive patients (P value 0.05). There was no correlation between Her-2 status
and response (P value 0.3). Conclusion: M30 level in serum is a useful
predictor marker of response to chemotherapy in both locally advanced and
metastatic breast cancer.